Brand Name

Tudorza Pressair

Generic Name
Aclidinium
View Brand Information
FDA approval date: July 01, 2015
Classification: Anticholinergic
Form: Powder

What is Tudorza Pressair (Aclidinium)?

TUDORZA® PRESSAIR® is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease . TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease .

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study.
Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study.
Journal: International journal of chronic obstructive pulmonary disease
Published: July 19, 2025
Effect of aclidinium bromide therapy on quality of life and symptoms of patients with chronic obstructive pulmonary disease: pooled analysis results of the Greek and Austrian ON-AIR real-world observational studies.
Effect of aclidinium bromide therapy on quality of life and symptoms of patients with chronic obstructive pulmonary disease: pooled analysis results of the Greek and Austrian ON-AIR real-world observational studies.
Journal: BMC pulmonary medicine
Published: May 28, 2025
Has FDA's Drug Development Tools Qualification Program Improved Drug Development?
Has FDA's Drug Development Tools Qualification Program Improved Drug Development?
Journal: Therapeutic innovation & regulatory science
Published: November 01, 2024
View All Latest Advances